Sageworth Trust’s Royalty Pharma RPRX Stock Holding History

Sageworth Trust’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-856	Closed	-$30.8K	–	372
2023 Q1	$30.8K	Buy	+856	New	+$31.7K	﹤0.01%	169

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sageworth Trust's RPRX Position: Q2 2023 in Review

Sageworth Trust sold out of Royalty Pharma (RPRX) in Q2 2023, closing a stake of 856 shares — an estimated $30.8K sold.

Sageworth Trust first reported a position in RPRX in Q1 2023 and held it in 1 quarter. The position peaked at $30.8K in Q1 2023. 325 funds tracked by Wall St. Rank hold RPRX as of Q2 2023.

Sageworth Trust reported no remaining Royalty Pharma position as of Q2 2023 after selling out during the quarter.
Sageworth Trust sold 856 Royalty Pharma shares in Q2 2023, an estimated $30.8K.
Sageworth Trust first reported a position in Royalty Pharma in Q1 2023 and held it in 1 quarter.
Sageworth Trust's Royalty Pharma position peaked at $30.8K in Q1 2023.
325 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2023.

Based on Sageworth Trust's 13F filing for Q2 2023, filed 26 Jul 2023.